AI in respiratory diseases market seen growing at 5% CAGR to 2030

The market for artificial intelligence in respiratory diseases is projected to rise from $7.98 billion in 2025 to $10.19 billion by 2030, according to The Business Research Company. Growth is being driven by rising respiratory illness, wider use of medical imaging, digital health adoption and demand for more personalized pulmonary care.

Why it matters: - AI is moving deeper into respiratory care, where faster diagnosis, better monitoring and more personalized treatment can affect outcomes for patients with chronic and acute lung disease. - The market’s projected growth signals more spending on AI tools that can support clinicians in imaging, prediction and disease management. - Environmental pollution is adding pressure to respiratory health systems and is increasing demand for digital tools that can track risk and guide care.

What happened: - The Business Research Company released its Artificial Intelligence (AI) Market in Respiratory Diseases Global Market Report 2026 – Market Size, Trends, And Forecast. - The report estimates the market will grow from $7.98 billion in 2025 to $8.38 billion in 2026. - The report projects the market will reach $10.19 billion by 2030. - The forecast implies a 4.9% CAGR from 2025 to 2026 and a 5.0% CAGR through 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period.

The details: - AI in respiratory diseases includes machine learning tools that help diagnose, manage and treat pulmonary conditions. - Applications include image analysis to detect abnormalities, predictive modeling to forecast disease progression and broader disease management. - Growth drivers include rising respiratory illness, expanded use of CT and MRI imaging, digitalization of healthcare records and early adoption of AI-assisted diagnostic tools. - Future growth is expected to come from demand for personalized respiratory care, greater integration with clinical decision support systems, remote monitoring for chronic respiratory patients, preventive pulmonology and advances in AI-driven medical imaging. - Pollution is listed as a major market driver because AI tools can support real-time monitoring, personalized risk assessments and clinical decision-making. - The report cites the November 2024 Global Carbon Budget, which said fossil carbon dioxide emissions rose to 37.4 billion tonnes, up 0.8% from the previous year. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company offers a free sample of the report here: Sample report. - The full report is available here: Full market report.

Between the lines: - The forecast suggests AI in respiratory care is shifting from experimental use toward a more routine role in hospital workflows and chronic disease management. - The combination of imaging, digital records and remote monitoring creates a stronger use case for AI than any single application alone. - Asia-Pacific’s faster growth points to a broader expansion of AI health tools in markets investing more heavily in medical infrastructure.

What’s next: - The market is expected to continue expanding through 2030 as healthcare systems add AI tools for diagnosis, monitoring and treatment planning. - Adoption will likely track hospital digitization, imaging volume and clinical demand for preventive and personalized care. - The company is positioning the report as a decision tool for market sizing, forecasting and technology planning.